References
- American Society of Addiction Medicine. (2020, June 30). COVID-19 - adjusting drug testing protocols. https://www.asam.org/Quality-Science/covid-19-coronavirus/adjusting-drug-testing-protocols
- Bhatraju, E. P., Grossman, E., Tofighi, B., McNeely, J., DiRocco, D., Flannery, M., Garment, A., Goldfeld, K., Gourevitch, M. N., & Lee, J. D. (2017). Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addiction Science & Clinical Practice, 12(1), 7. https://doi.org/https://doi.org/10.1186/s13722-017-0072-2
- Drug Enforcement Agency (DEA). (2020, March). DEA SAMHSA buprenorphine telemedicine. https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf.
- Eibl, J. K., Gauthier, G., Pellegrini, D., Daiter, J., Varenbut, M., Hogenbirk, J. C., & Marsh, D. C. (2017). The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug and Alcohol Dependence, 176, 133–138. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2017.01.048
- Haley, D. F., & Saitz, R. (2020). The opioid epidemic during the COVID-19 pandemic. JAMA, 324(16), 1615–1617. https://doi.org/https://doi.org/10.1001/jama.2020.18543
- Han, B. H., Doran, K. M., & Krawczyk, N. (2022). National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness. Journal of Substance Abuse Treatment, 132, 108504. Advance online publication. https://doi.org/https://doi.org/10.1016/j.jsat.2021.108504
- Jakubowski, A., & Fox, A. (2020). Defining low-threshold buprenorphine treatment. Journal of Addiction Medicine, 14(2), 95–98. https://doi.org/https://doi.org/10.1097/ADM.0000000000000555
- Kruse, C. S., Lee, K., Watson, J. B., Lobo, L. G., Stoppelmoor, A. G., & Oyibo, S. E. (2020). Measures of effectiveness, efficiency, and quality of telemedicine in the management of alcohol abuse, addiction, and rehabilitation: Systematic review. Journal of Medical Internet Research, 22(1), e13252. https://doi.org/https://doi.org/10.2196/13252
- Parker, S., Prince, A., Thomas, L., Song, H., Milosevic, D., & Harris, M. F. (2018). Electronic, mobile and telehealth tools for vulnerable patients with chronic disease: a systematic review and realist synthesis. BMJ Open, 8(8), e019192. https://doi.org/https://doi.org/10.1136/bmjopen-2017-019192
- Slavova, S., Rock, P., Bush, H. M., Quesinberry, D., & Walsh, S. L. (2020). Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug and Alcohol Dependence, 214, 108176. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.108176
- Snow, R. L., Simon, R. E., Jack, H. E., Oller, D., Kehoe, L., & Wakeman, S. E. (2019). Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. Journal of Substance Abuse Treatment, 107, 1–7. https://doi.org/https://doi.org/10.1016/j.jsat.2019.09.003
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2020). FAQs: Provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf.
- Tofighi, B., McNeely, J., Walzer, D., Fansiwala, K., Demner, A., Chaudhury, C. S., Subudhi, I., Schatz, D., Reed, T., & Krawczyk, N. (2022). A telemedicine buprenorphine clinic to serve New York City. Journal of Addiction Medicine, 16(1), e40–e43. https://doi.org/https://doi.org/10.1097/ADM.0000000000000809
- Tofighi, B., Williams, A. R., Chemi, C., Suhail-Sindhu, S., Dickson, V., & Lee, J. D. (2019). Patient barriers and facilitators to medications for opioid use disorder in primary care. Substance Use & Misuse, 54(14), 2409–2419. https://doi.org/https://doi.org/10.1080/10826084.2019.1653324
- Wang, L., Weiss, J., Ryan, E. B., Waldman, J., Rubin, S., & Griffin, J. L. (2021). Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 124, 108272. https://doi.org/https://doi.org/10.1016/j.jsat.2020.108272
- Zheng, W., Nickasch, M., Lander, L., Wen, S., Xiao, M., Marshalek, P., Dix, E., & Sullivan, C. (2017). Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: A 2-year retrospective data analysis. Journal of Addiction Medicine, 11(2), 138–144. https://doi.org/https://doi.org/10.1097/ADM.0000000000000287